Gilead: HIV-Prüfpräparat erreicht primären Endpunkt in Phase-3-Studie
| ... HIV-Einzeltabletten-Regime, das Bictegravir und Lenacapavir (BIC/LEN) kombiniert, in der klinischen Phase-3-Studie ARTISTRY-1 seinen primären ... |
German general says Russia could launch limited attack on NATO any timeGerman general says Russia could launch limited attack on NATO any time
"Small, quick, regionally limited, nothing big - Russia is too tied down in Ukraine for that." Sollfrank , who heads Germany 's joint operations command ... View article...